News Breaks |
|
|
| March 20, 2013 |
| 08:04 EDT |  | OMPI, VRX | Valeant agrees to acquire Obagi Medical for $19.75 per share
Valeant announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19. The transaction is expected to close in the first half of 2013 and Valeant expects the transaction, once completed, to be immediately accretive to Valeant's cash earnings per share. The combination is expected to yield cost synergies at an annual run rate of at least $40 million within six months of closing. Obagi had total revenue of approximately $120 million in 2012. Following the successful completion of the tender offer, a wholly owned subsidiary of Valeant will merge with Obagi and the outstanding Obagi shares not tendered in the tender offer will be converted into the right to receive the same $19.75 per share in cash paid in the tender offer. Obagi's board of directors has unanimously approved the transaction. |
|
|
News For VRX;OMPI From The Last 14 Days Check below for free stories on VRX;OMPI the last two weeks. |
|
|
| June 17, 2013 |
| 16:03 EDT |  | VRX | Valeant files to sell $1.75B of common stock
Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada will act as sole manager of the Offering in Canada. |
|
| June 11, 2013 |
| 07:31 EDT |  | VRX | Goldman to host a conference
 Subscribe for More Information |
|
| June 10, 2013 |
| 10:04 EDT |  | VRX | On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alexandria Real Estate (ARE) upgraded to Buy from Neutral at ISI Group... BB&T (BBT) upgraded to Overweight from Equal Weight at Evercore... CyrusOne (CONE) upgraded to Strong Buy from Outperform at Raymond James... EQT Corporation (EQT) upgraded to Buy from Hold at Brean Capital... Edwards Lifesciences (EW) upgraded to Outperform from Neutral at Credit Suisse... Enersis (ENI) upgraded to Buy from Neutral at Citigroup... Entergy (ETR) upgraded to Buy from Hold at Deutsche Bank... Monsanto (MON) upgraded to Outperform from Neutral at Macquarie... Regency Centers (REG) upgraded to Buy from Neutral at ISI Group... Silver Standard (SSRI) upgraded to Hold from Sell at Deutsche Bank... Standard Pacific (SPF) upgraded to Neutral from Underweight at JPMorgan... Stericycle (SRCL) upgraded to Buy from Hold at Wunderlich... WABCO (WBC) upgraded to Buy from Neutral at Goldman... Western Union (WU) upgraded to Outperform from Market Perform at Raymond James... Weyerhaeuser (WY) upgraded to Outperform from Sector Perform at RBC Capital... Washington Trust Bancorp (WASH) upgraded to Buy from Hold at Sandler O'Neill... EastGroup Properties (EGP) upgraded to Buy from Hold at Sandler O'Neill... Valeant (VRX) upgraded to Buy from Fair Value at CRT Capital... RF Micro Devices (RFMD) upgraded to Strong Buy from Buy at Charter Equity... Bank of the Ozarks (OZRK) upgraded to Outperform from Market Perform at Raymond James... United Community Banks (UCBI) upgraded to Outperform at Raymond James... Western Union (WU) upgraded at Raymond James... CyrusOne (CONE) upgraded to at Raymond James... AT&T (T) upgraded to Buy from Hold at Argus... IMAX (IMAX) upgraded to Buy from Neutral at B. Riley... TriMas (TRS) upgraded to Outperform from Market Perform at Barrington. |
|
| 08:58 EDT | | VRX | Valeant upgraded to Buy from Fair Value at CRT Capital
CRT Capital upgraded Valeant based on valuation and the Bausch + Lomb acquisition. Price target is $100. |
|
| 07:37 EDT | | VRX | Valeant files automatic common shelf offering
Subscribe for More Information |
|
| June 7, 2013 |
| 14:38 EDT | | VRX | Valeant confirms plans for financing of Bausch + Lomb acquisition
As previously disclosed by the company, Valeant has entered into a definitive agreement under which it will acquire Bausch + Lomb Holdings Incorporated. The company confirms its expectation that such transaction will be financed with debt and approximately $1.5B-$2.0B of new equity. Concurrently, Valeant announced the filing of a preliminary base shelf prospectus for up to $3B in common shares. |
|
| 14:30 EDT | | VRX | Valeant announces $3B common stock offering
Subscribe for More Information |
|
|
|
|
|
